Parsaclisib Has Activity in Patients with B-cell Malignancies.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2019-031
Abstract: A next-generation PI3Kδ inhibitor achieved objective responses and long-term tolerability in NHL. read more here.
Keywords: parsaclisib activity; cell malignancies; patients cell; activity patients ... See more keywords